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Photodynamic Therapy (PDT) using 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) has 
been considered as a new method for treating neoplasms. However, ALA-PDT is suboptimal for thick 
tumors. Searching for new approaches, we investigated the effect of adding differentiation therapy (DT) 
with Vitamin E succinate (VES) to PDT in human prostate LN-CaP-FGC10 cancer cells in vitro. The 
purpose of DT was to reverse the lack of differentiation in cancer cells and to enhance the effectiveness of 
ALA- dependent PDT. 
Three groups of cells were grown on RPMI1640 culture medium supplemented with 10% FBS. The cells 
included: ALA-PDT cells, which received 0.3 mM ALA for 4 hours at dark, and exposed to 532 nm, 50 
mW Nd-YAG laser beam for 3 min; DT+ALA-PDT cells, which received 6 µg/ml
 
VES for 24, 48 and 72 
hours, followed by the addition of 0.3 mM ALA for 4 h and exposure to Nd-YAG laser beam for 3 min; 
control cells which were untreated. After 24 h, the percentage of cell viability was determined by MTT 
assay. Accumulation of PpIX was measured by spectrophotometry and fluorescent microscopy. Mechanism 
of induced cell death was investigated via Hoechst staining. The combination of both factors (VES and 5-
ALA) lead to a significant increase in cell death after 72 h. Induction of differentiation augmented PpIX 
accumulation in cells treated with ALA. Elevated intracellular PpIX levels resulted in an enhanced lethal 
photodynamic sensitization of VES plus ALA-treated cells after 72 h. Apoptotic cell death by both ALA-
PDT and VES-ALA-PDT was confirmed by Hoechst staining. Our data suggest that VES used in 
combination with 5-ALA may provide a new combinatorial approach for treating certain cancers. 
 




Prostate cancer is the most common type of 
cancer among men of 65 years and older. It is 
also the second leading cause of cancer-related 
deaths in men. There are a variety of cancer 
treatments, including hormone therapy, radio 
therapy, chemo therapy and surgery (radical 
prostatectomy). However, none of these 
approaches lead to an absolute cure, and the 
number of treatment failures remain 
unacceptable [1, 2]. Photodynamic therapy 
(PDT) is an experimental cancer treatment 
modality, in which systemic administration of a 
tumor-localizing photosensitizer (Ps) is followed 
by irradiation of the tumor with visible light of 
an appropriate wavelength. The photochemical 
interaction of Ps-light and the molecular oxygen 
results in the production of reactive oxygen 
species (ROS) [3, 4]. 
   Damage to organelles within the malignant 
cells and to stromal elements of the tumors lead 
to tumor ablation [5, 6]. Membranous organelles, 
including mitochondria, plasma membrane and 
lysosomes have been suggested as the major 
targets of PDT damage [7]. Since cancer cells 
administered by the pro-drug 5-ALA (5-
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aminolevulinic acid) exhibit enhanced capacity for PpIX synthesis both in vitro and in solid 
tumors, this enhanced capacity was recently 
exploited clinically for PDT and photodiagnosis 
[8, 9]. Fluorescent microscopy data have 
indicated that due to the localization of PpIX in 
mitochondria, the primary cause of cell death 
following PDT is mitochondrial phototoxicity 
[10]. However, ALA-PDT is suboptimal for thick 
or refractory tumors. So, new modalities are 
needed, including ways to increase the clinical 
responsiveness of tumor cells to ALA-PDT [11]. 
One promising approach to improve the efficacy 
of ALA-PDT cell death is to alter the biological 
responses of the target cancer cells in a manner 
that would enhance susceptibility to ALA- 
mediated PDT [12]. Differentiation therapy (DT), 
as an alternative modality, can help increase 
responses of cancer cells to PDT, since malignant 
cells typically do not progress through the normal 
process of growth arrest. Differentiation, 
apoptosis and cellular proliferation of cancer cells 
are due to a block in maturation. DT can 
reactivate the tumor cell differentiation program, 
forcing them to resume maturation and eventually 
undergo normal apoptosis [12, 13]. Vitamin E 
succinate (VES) (α-tocopherol succinate = αTS) 
is the most active form of vitamin E compared to 
α-tocopherol, α-tocopherol acetate and α-
tocopherol nicotinate. α-TS induces 
differentiation, inhibits proliferation and causes 
apoptosis in cancer cells without affecting the 
proliferation of most normal cells [14, 15, 16]. It 
has been proven that VES can cause LN-CaP cell 
growth arrest at G1 phase of the cell cycle [16]. 
Since VES induces cellular differentiation in 
many tumor cells, and agents capable of inducing 
differentiation will also cause elevated synthesis 
of PpIX after ALA administration in epithelial 
cells of the skin and prostate [17], we utilized a 
combination regimen involving DT, and using 
VES, followed by ALA-PDT in order to enhance 
the efficacy of ALA-PDT cell death. Our findings 
indicated that using VES for 72 h may represent a 
useful adjunct to ALA-PDT in managing prostate 
cancer. 
 
MATERIALS AND METHODS 
 
   ALA and Vitamin E Succinate (VES) were 
purchased from Sigma (USA). Hoechst 33432 
was obtained from Sigma-Aldrich (USA). ALA 
was dissolved in Phosphate Buffer Saline (PBS) 
(pH 7.2) and sterilized with a 0.2 µm filter, and 




   LN-CaP-FGC10 cell line, a human prostate 
cancer cell line, was obtained from the Pasteur 
Institute of Iran and grown in RPMI1640 medium 
containing  10% Fetal Bovine Serum (FBS) 
(Gibco, USA) supplemented with L-glutamine 
(Sigma, USA) and 1% antibiotic (Penicilin-
Stereptomycin) at 37 °C in a humidified, 5% CO2 
incubator. Cells were maintained subconfluent 
and passaged twice weekly. All experiments were 




   LN-CaP-FGC10 cells were plated in 24-well 
plates at a density of 2×10
4 
cells per well. After 
24 h, the medium was changed with one 
containing 10% FBS (GIBCO, USA). Then, VES 
(as a differentiation agent) was diluted in the 
medium and immediately added to the cells, 
incubated for 24, 48 and 72 h. Controls were 
untreated and grown in RPMI1640 medium with 
10% FBS. 
 
Measurement of PpIX synthesis 
 
   Cells were seeded at a density of 2×10
4 
cells/well in 24-well plates. The medium was 
replaced after 24 hours. Five groups of cells 
included: the control group (untreated); ALA 
group (cells were resuspended in 1 ml fresh 
serum-free medium containing 0.3 µM ALA and 
incubated for 4 h in the dark; Three different 
VES-ALA groups (following DT with vitamin E 
for 24, 48, and 72 h, cells were treated with 1 ml 
fresh medium containing 0.3 µM ALA and 
incubated for 4 h in the dark). Cells in each group 
were then solubilized in 0.1 N NaOH containing 
1% Sodium Dodecyl Sulfate (SDS). Next, the 
cell lysates were submitted to fluorescence 
spectrophotometry (Cary Eclips, Australia) 
(excitation 400 nm, emission 580-720 nm, peak 
630 nm). 
 
Analysis of PpIX in living cells by fluorescence 
microscopy 
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   Sterilized coverslips were placed in each well 
of a 12-well plate, and cells were placed on the 
coverslips. The medium was replaced after 24 h. 
Three groups including control, ALA and VES-
ALA-72 h were included. Fluorescence of PpIX 
was analyzed by fluorescence microscopy (Zeiss, 
West Germany) using a green filter (excitation 
480 nm). 
 
In vitro Photodynamic treatment 
 
   For phototoxicity, cells were incubated in a 
serum-free medium containing 0.3 µM ALA. 
After 4 h, cells were exposed to 532 nm, 50 mW 
continuous wave Nd-YAG laser (class 3B, 400-
700 nm, Germany). To distribute the laser beam 
(uniform irradiation), a 10 cm lens was utilized.  
MTT viability assay 
 
 
   Mitochondrial dehydrogenase activity was 
quantified by MTT assay. To evaluate PDT effect 




bromide) was added to each well after 24 h post-
treatment and incubated at 37 ˚C for 3-4 h. 
Isopropyl alcohol containing 0.04 mM HCl was 
added and incubated for 5 h. The optical 
absorbance was determined at 570 nm in a 
spectrophotometer. Percentage of cell viability 
was calculated as( optical dencity of treated 




Before and after each treatment, cells in all 
groups were scored based on their morphological 
appearance using an invert microscope. 
 
Assessment of apoptosis and necrosis in ALA-
PDT and VitE-ALA-PDT by Hoechst staining 
of cells 
 
   Hoechst 33342 stains the nucleus of viable and 
apoptotic cells, which are distinguished by their 
morphology. For this procedure, three groups of 
cells (Control, ALA-PDT and VES-ALA-PDT) 
were seeded in sterilized coverslips, as indicate 
above. After 24 h, cells were stained with 
Hoechst dye (5 µg/ml). Then, coverslips were 
placed on glass slides and fluorescence was 
monitored through a green filter (450-490 nm) 
under a fluorescent microscope. Cells with 




   Data were expressed as mean ± standard error 
of the mean (SEM). Statistical comparisons were 
made by the analysis of variance (ANOVA) 
(InStat), and when significant differences were 
observed, a P-value of 0.05 was considered as 
statistically significant.  
 
RESULTS 
Effect of ALA-PDT and DT(VES)-ALA-PDT 
on viability of LN-CaP-FGC10 cells 
 
   Our results indicated that ALA-PDT with 0.3 
µM ALA followed by Nd-YAG laser beam (532 
nm, 50 mW) treatment reduced cell survival to 
58.5%. Cell viability in VES-ALA-PDT after 24, 
48 and 72 h were 51%, 44.5% and 29%, 
respectively, while a 72 h DT with 6 µg/ml
 
VES 





Figure 1. Phototoxicity effect of ALA-PDT and VES-ALA- 
PDT on cell survival as compared to control using MTT 
assay. DT groups received 6µg/ ml   VES for 24, 48 and 72h, 
followed by 0.3mM ALA for 4h at dark, and Nd-YAG laser 
beam (532nm,50mW for 3 min). (*P<0.05, **P<0.01, 
***P<0.001). Mean±SEM. 
 
72 h VES significantly enhances ALA-induced 
PpIX in LN-CaP-FGC10 cells 
 
   To evaluate the effect of VES as a 
differentiation agent on ALA-PDT treatment, 
LN-CaP-FGC10 cells were incubated with 6 
µg/ml VES for 24, 48 and 72 h. 
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Spectrophotometric quantification of PpIX 
demonstrated that ALA-PDT efficiency was 
enhanced significantly (P<0.001) after 72 h of 
incubation with VES (Figure 2).  
 
 
Figure 2. Time dependent VES-induced PpIX accumulation. 
Cells in DT groups were exposed to 6µg/ml VES for 24, 48 
and 72h, followed by 0.3mM ALA for 4h at dark. (*P<0.05, 
**P<0.01, ***P<0.001). Mean±SEM. 
 
 
VES-treated living cells were also analyzed 
under a fluorescent microscope for PpIX 
accumulation. The highest PpIX fluorescence 
was obtained after a 72 h   treatment with 6 
µg/ml
 
VES (Figure 3).   
 
 
Figure 3. PpIX fluorescence in living cells. 24 hours after cultured cells were incubated with a medium containing VES (6µg/ml) 
(for 72h) or without VES, followed by 0.3mM ALA for 4h at dark. Fluorescence of PpIX was analyzed by a fluorescent 
microscope. 
 
Effect of ALA-PDT and VES-ALA-PDT on 
cell morphology 
 
   Before and after treatments, LN-CaP-FGC10 
cells were examined under an invert microscope. 
24 hours after the differentiation therapy started,  
cells showed slight elongation, and these changes 
in cell shape were further pronounced in 72 h. 
ALA-PDT and VES-ALA-PDT resulted in the 











Figure 4. Inverted photomicrographs of LN-CaP-FGC10 cells. a) cells without treatment. b) cells after a 72h differentiation therapy. 
c) cells after administration of 0.3 mM ALA and 532nm Nd-YAG laser beam. d) cells after VES (72h) ALA-PDT (6µg/ml VES for 
72h, 0.3 mM ALA, 532nm Nd-YAG laser beam). Arrows in b indicate differentiating cells. Cell shape deformation is obvious in c 
and d. 
 
Analysis of cell death induced by ALA-PD and 
VES-ALA-PDT 
   To determine whether VES treatment along 
with ALA-PDT induces apoptosis in LN-CaP-
FGC10 cells, Hoescht staining was performed 
and cells were examined under a fluorescent 
microscope. Data from Hoescht staining revealed 
normal chromatin in control group, whereas in 
ALA-PDT and VES-ALA-PDT groups 
condensed and fragmented nuclei (two important 




Figure 5. Fluorescence micrografs of LN-CaP-FGS-10 cells stained by Hoescht dye. a and c) cells with normal chromatin (arrows). 




   The basis for photodynamic therapy is a 
selective accumulation of a certain 
photosensitizing agent in neoplastic tissue 
without affecting the healthy tissue. Activation 
of the photosensitizer by a specific wavelength 
of light could result in the production of 
cytotoxic singlet oxygen and ROS, leading to the 
death of tumor cells. PDT using 5-ALA as a pro-
drug that is converted to an intracellular Ps 
(PpIX) is widely used for treatment of rapidly 
proliferating cells, especially the solid tumors. 
However, ALA-mediated PDT is suboptimal for 
treatment of deeper tumors, and the number of 
treatment failures remains unacceptable. Cancer 
development and progress is a complex process 
[4, 18, 19, 20]. In malignant cells, genomes are 
changed and mechanisms leading to apoptosis 
are defective. In vitro and in vivo studies as well 
as various clinical trials are making it 
increasingly evident that no single therapeutic 
modality could be a likely curative. So, a 
combination regimen is more likely to destroy 
malignant cells [12, 21]. In this study, we 
demonstrated a combination treatment utilizing 
differentiation therapy and PDT in order to 
enhance the cytotoxic effects on prostate cancer 
cells. ALA-induced PpIX production was 
markedly increased in LN-CaP cells after 
treatment with the differentiation agent VES, the 
most effective form of vitamin E, resulting in a 
significant enhancement of phototoxicity in the 
 
Journal of Paramedical Sciences (JPS)                       Summer 2011 Vol.2, No.3 ISSN 2008-4978       
21 
 
differentiated cells. While ALA-PDT reduced 
LN-CaP cell survival to 58.5%, DT with VES for 
24, 48 and 72 h followed by ALA-PDT reduced 
LN-CaP cell survival to 51%, 44.5% and 29%,  
respectively. A marked reduction in cell viability 
was observed after 72 h of DT with VES 
followed by ALA-PDT. 
Since the arrest of cell cycle is a prerequisite for 
differentiation, and differentiation eventually 
results in cell death in many systems, these 
associations are utilized by DT, restoring the 
pathways lost in malignant cells [12]. 
Application of ATRA (all-trans retinoic acid) as  
a differentiating agent for treatment of APML 
(acute promyelocyte leukocyte) was the typical 
clinical DT program used by Breitman et al [22] 
to induce differentiation of the cancer cells 
leading to their apoptosis. 
   As described earlier, four parameters are 
required for an effective PDT: the 
photosensitizing agent, light, oxygen and cellular 
physiology. By proper manipulation of the 
cellular metabolic state, we  obtained  a  higher  
level of PpIX. This increase in the cellular PpIX 
content led to an improved photodynamic 
sensitization. Several other agents such as 
methotrexate, androgens, vitamin A and analogs 
of vitamin D also promote cellular 
differentiation, and by enhancing PpIX 
accumulation in LN-CaP cells improve 
photodynamic efficacy [11, 12]. Schwartz et al 
[23]
 
used Hexa Methylen Bis Acetamide 
(HMBA) and butyrate followed by ALA-PDT 
and showed that HMBA and butyrate increase 
the rate of ALA-PDT- induced cell death. They 
further demonstrated that HMBA was a 
prominent inducer of PpIX accumulation. 
Esquent et al [24] used R1881 as a modulator of 
differentiation in LN-CaP cells. This agent 
arrested cell growth by reducing DNA synthesis. 
However, not all differentiating agents are 
capable  of   elevating   PpIX   formation.   For  
instance, Schoenfield et al [25]
 
suggested that 
DT treatment with DMSO had no stimulatory 
effect on PpIX synthesis. Almedia et al [26] 
reported that cell death induced by PDT is due to 
apoptosis or necrosis depending on the cell 
genotype, the photosensitizer and the PDT dose. 
However, even for a specific Ps used for PDT, 
the unique type of cell death is difficult to 
determine [27]. 
   Accumulation of PpIX in differentiated cancer 
cells may be due to several factors: a) an 
increased uptake of ALA, b) a higher metabolic 
activity in tumor cells, c) a reduced efflux of 
PpIX into the medium, d) an increase in the 
mRNA of haem synthetic enzyme and e) a lower 
enzymatic activity of ferrochelatase
 
[17, 28]. Our 
results demonstrated a high level of induction of 
apoptosis by ALA-PDT as revealed by Hoechst 
staining using fluorescence microscopy. Cells 
with condensed and fragmented nuclei (two 
important characteristics of apoptosis) were 
considered as apoptotic. 
   In summary, our results suggest that VES(72 
h)-ALA-PDT by elevating the production of 
endogenous PpIX can enhance the efficacy of 
PDT in killing cells. Our data support the 
importance of differentiation in ALA-mediated 
PpIX formation, making the future clinical 
protocols less toxic for normal tissues and more 
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